Immune · Immune peptide (research)
LL-37
- Drug class
- Immune peptide (research)
- Status
- Compounded (503A)
- Reviewed
- 2026-06-01 · Dr. Ana Lisa Carr, MD
What LL-37 is studied for
- Antimicrobial activity (research)
- Gut health (research)
- Microbiome balance (research)
Mechanism of action
LL-37 is being studied in the immune category. Human antimicrobial peptide for gut and immune defense. Mechanism of action varies by study model; refer to the kindr clinical library for a deeper writeup.
Frequently asked questions
What is LL-37?
LL-37 is a immune peptide. Human antimicrobial peptide for gut and immune defense.
What is LL-37 studied for?
Published research has examined LL-37 for antimicrobial activity, gut health, microbiome balance. Human clinical evidence varies by indication.
Is LL-37 FDA-approved?
No. LL-37 is not FDA-approved for the indications listed. It is available compounded by 503A pharmacies under clinician supervision, or for international research use only on this catalog.
How is LL-37 used in research?
Protocols vary by study. LL-37 is typically administered subcutaneously in research settings. No validated human therapeutic dose exists outside FDA-approved indications.
What are the known risks?
Long-term human safety data for LL-37 is limited. Theoretical risks vary by mechanism. Any human use should be supervised by a licensed clinician.